Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juan Tamargo

Showing results (11-20 of 184) with videos related to

Pageof 19
Sort By:
Revista Espanola De Cardiologia|May 21, 2004
[Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure]Juan Tamargo, José López-Sendón
Future Cardiology|November 29, 2021
Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable anginaJuan Tamargo, Jose Lopez-Sendon
Nature Reviews. Drug Discovery|June 25, 2011
Novel therapeutic targets for the treatment of heart failureJuan Tamargo, José López-Sendón
Expert Opinion on Investigational Drugs|December 8, 2018
New drugs in preclinical and early stage clinical development in the treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Review of Cardiovascular Therapy|August 4, 2011
Ranolazine: an antianginal drug with antiarrhythmic propertiesJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|May 16, 2021
Sex-related differences in the pharmacological treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|January 7, 2026
SGLT2 inhibitors: Do they have antiarrhythmic properties?Ricardo Caballero, Juan Tamargo, Eva Delpón
Discovery Medicine|November 27, 2014
New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope?Juan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Pharmacotherapy|February 23, 2021
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular diseaseJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Drug Safety|April 14, 2006
The safety of digoxin as a pharmacological treatment of atrial fibrillationJuan Tamargo, Eva Delpón, Ricardo Caballero
Pageof 19

Showing results (11-20 of 184) with videos related to

Sort By:
Pageof 19
Revista Espanola De Cardiologia|May 21, 2004
[Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure]Juan Tamargo, José López-Sendón
Future Cardiology|November 29, 2021
Ranolazine: a better understanding of its pathophysiology and patient profile to guide treatment of chronic stable anginaJuan Tamargo, Jose Lopez-Sendon
Nature Reviews. Drug Discovery|June 25, 2011
Novel therapeutic targets for the treatment of heart failureJuan Tamargo, José López-Sendón
Expert Opinion on Investigational Drugs|December 8, 2018
New drugs in preclinical and early stage clinical development in the treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Review of Cardiovascular Therapy|August 4, 2011
Ranolazine: an antianginal drug with antiarrhythmic propertiesJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|May 16, 2021
Sex-related differences in the pharmacological treatment of heart failureJuan Tamargo, Ricardo Caballero, Eva Delpón
Pharmacology & Therapeutics|January 7, 2026
SGLT2 inhibitors: Do they have antiarrhythmic properties?Ricardo Caballero, Juan Tamargo, Eva Delpón
Discovery Medicine|November 27, 2014
New drugs for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors -- hype or hope?Juan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Pharmacotherapy|February 23, 2021
The pharmacotherapeutic management of hyperkalemia in patients with cardiovascular diseaseJuan Tamargo, Ricardo Caballero, Eva Delpón
Expert Opinion on Drug Safety|April 14, 2006
The safety of digoxin as a pharmacological treatment of atrial fibrillationJuan Tamargo, Eva Delpón, Ricardo Caballero
Pageof 19